Xoft - Non-Surgical Skin Cancer Treatment in Midland, TX
Looking for skin cancer treatment in Midland, Texas? Consider Xoft Brachytherapy at Midland Dermatology. If you have been diagnosed with non-melanoma skin cancer, such as basal or squamous cell carcinoma, you may have concerns about scarring, wound healing or preserving functionality in anatomically challenging areas.
What is Xoft?
Xoft is an advanced, patient-friendly option for non-melanoma skin cancer (NMSC) treatment. Xoft provides an effective and convenient alternative to surgery, which allows patients to return to normal activities immediately with no downtime.
What are the benefits of Xoft?
Xoft provides patients with a targeted, non-invasive alternative to surgery for non-melanoma skin cancer treatment. While surgery is considered to be the standard of care for non-melanoma skin cancer, for some patients, surgery is not an option or a preference. Xoft offers a completely non-invasive approach, with no cutting, bleeding or stitching required. Xoft offers patients and physicians a safe and effective treatment option for non-melanoma skin cancer with valuable benefits including:
- Excellent clinical and cosmetic results1
- No downtime
- Quick treatment sessions
- Precise targeting
- No pain, anesthesia, cutting, bleeding or stitching
- No need for post-treatment reconstructive surgeries
- Ideal for challenging anatomic locations
Is Xoft right for you?
Schedule an appointment to determine if Xoft may be right for you. Appropriate candidates for Xoft may include the following patients:
- Patients with lesions in anatomically challenging locations
- Patients who prefer an alternative to surgery
- Patients who are not surgical candidates, due to medical comorbidities or other health issues such as diabetes, peripheral vascular disease or blood-thinning medication
- Patients with higher-risk lesions, including features such as positive margins, requiring adjunct therapy to surgery
- Patients with busy schedules
How does Xoft work?
Xoft uses a miniaturized x-ray source to deliver a precise radiation dose to your cancer lesion. This targeted treatment directs the radiation to the size and shape of the cancerous area, carefully destroying cancer cells and sparing surrounding healthy tissue.
From the market leader in skin electronic brachytherapy, Xoft offers a safe and effective outpatient option delivering excellent clinical and cosmetic results. More than 10,000 non-melanoma skin cancer patients have been successfully treated with Xoft.
Treatment requires approximately six to eight brief visits to Midland Dermatology. An individualized treatment regimen and prescription, including customized shielding, will be recommended by your skin cancer specialist based on your age, medical history, the type, size and location of your cancer, as well as other criteria. Xoft is administered in just five simple steps. The Xoft treatment dosage is planned by a radiation oncologist or specialist in radiation treatment.
Xoft Treatment Plan
- A clinician will prepare a customized set-up designed to target the lesion while protecting surrounding healthy tissue.
- A small surface applicator is placed on the skin where the radiation is to be delivered.
- The miniaturized x-ray source is placed in the applicator and energized to deliver a precise, prescribed dose of radiation.
- Radiation is delivered in just a few minutes in a standard exam room while medical personnel remain in the room.
- Once the treatment is complete, customized treatment devices are removed. The patient is able to return to normal activities immediately.
Schedule an appointment at Midland Dermatology to determine if you may be an appropriate candidate for Xoft, a painless, non-surgical solution for non-melanoma skin cancer treatment right here in Midland, Texas. For more information or to schedule an appointment, call 432-689-2512.
- A Bhatnagar, et al. High-dose Rate Electronic Brachytherapy: A Nonsurgical Treatment Alternative for Nonmelanoma Skin Cancer. The Journal of Clinical and Aesthetic Dermatology; Nov. 2016; Vol. 9; No.11: 16-22